Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 4/20 | 0.40 |
| ▸ | KDM5A | P29375 | 2/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | KDM4A | O75164 | 3/20 | 0.38 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.38 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.38 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4699893 | 0.94 | TSHR (0.47) | TSHRALDH1A1EPHX2LMNAKDM4C | |
| SCHEMBL4700836 | 0.92 | EPHX2 (0.49) | TSHRALDH1A1EPHX2LMNAKDM4C | |
| SCHEMBL9575098 | 0.89 | TSHR (0.43) | TSHRALDH1A1LMNAKDM4CKDM5A | |
| SCHEMBL14379958 | 0.83 | PAOX (0.43) | TSHRALDH1A1LMNA | |
| SCHEMBL8381207 | 0.83 | LMNA (0.38) | TSHRLMNA | |
| SCHEMBL8381205 | 0.82 | LMNA (0.37) | TSHRLMNA | |
| SCHEMBL10906138 | 0.80 | TSHR (0.45) | TSHRALDH1A1LMNASLC22A6KDM4C | |
| SCHEMBL14707175 | 0.79 | MEN1 (0.42) | TSHRALDH1A1LMNA | |
| SCHEMBL693386 | 0.79 | HDAC6 (0.40) | TSHRALDH1A1EPHX2LMNASLC22A6 | |
| SCHEMBL22282294 | 0.78 | LMNA (0.40) | TSHRALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114380717-A | Process for the preparation of 3- (tert-butoxycarbonyl-methoxycarbonylmethyl-amino) -propionic acid methyl ester and intermediates thereof | 郑州猫眼农业科技有限公司 | 2022-04-22 | — | — | CN | disclosed |
| CN-114380717-A | Process for the preparation of 3- (tert-butoxycarbonyl-methoxycarbonylmethyl-amino) -propionic acid methyl ester and intermediates thereof | 郑州猫眼农业科技有限公司 | 2022-04-22 | — | — | CN | disclosed |
| EP-3541857-A1 | CATALYST COMPONENTS FOR THE POLYMERIZATION OF OLEFINS | Basell Poliolefine Italia S.r.l. (IT) | 2019-09-25 | — | — | EP | disclosed |
| WO-2018091375-A1 | CATALYST COMPONENTS FOR THE POLYMERIZATION OF OLEFINS | BASELL POLIOLEFINE ITALIA S.R.L. (IT) | 2018-05-24 | — | — | WO | disclosed |
| EP-2601188-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-18 | — | — | EP | disclosed |
| EP-1599471-B1 | HYDROXYMETHYL SUBSTITUTED DIHYDROISOXAZOLE DERIVATIVES USEFUL AS ANTIBIOTIC AGENTS | ASTRAZENECA AB (SE) | 2008-05-28 | — | — | EP | disclosed |
| US-7192974-B2 | Hydroxymethyl substituted dihydroisoxazole derivatives useful as antibiotic agents | ASTRAZENECA AB (SE) | 2007-03-20 | — | — | US | disclosed |
| US-20060270637-A1 | Hydroxymethyl substituted dihydroisoxazole derivatives useful as antibiotic agents | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | US | disclosed |
| EP-1599471-A1 | HYDROXYMETHYL SUBSTITUTED DIHYDROISOXAZOLE DERIVATIVES USEFUL AS ANTIBIOTIC AGENTS | Astrazeneca AB (SE) | 2005-11-30 | — | — | EP | disclosed |
| WO-2004078753-A1 | HYDROXYMETHYL SUBSTITUTED DIHYDROISOXAZOLE DERIVATIVES USEFUL AS ANTIBIOTIC AGENTS | ASTRAZENECA AB (SE) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270637-A1 | Hydroxymethyl substituted dihydroisoxazole derivatives useful as antibiotic agents | RPS7, CYP3A7, CYP2A7 | TSHR 1044/4885ALDH1A1 421/4885EPHX2 1851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.